Trial Profile

A randomized, single blind, repeat dose, placebo-controlled, single-period, parallel group study to investigate the safety, tolerability and potential pharmacokinetic interactions between GW856553 and rosuvastatin (10mg), when co-administered in healthy adult male subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Losmapimod (Primary) ; Rosuvastatin
Indications Acute coronary syndromes; Atherosclerosis; Cardiovascular disorders; Chronic obstructive pulmonary disease; Depressive disorders; Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia; Rheumatoid arthritis
Focus Pharmacokinetics
Sponsors GSK

01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
20 May 2009 Exclusion criteria amended from NCT
21 Apr 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com